MNG103
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.556
- OXIDATIVE_PHOSPHORYLATION+0.497
- MYC_TARGETS_V2+0.494
- E2F_TARGETS+0.433
- G2M_CHECKPOINT+0.406
- MTORC1_SIGNALING+0.333
- UNFOLDED_PROTEIN_RESPONSE+0.320
- CHOLESTEROL_HOMEOSTASIS+0.296
- DNA_REPAIR+0.264
- WNT_BETA_CATENIN_SIGNALING+0.226
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.436
- TNFA_SIGNALING_VIA_NFKB-0.409
- INTERFERON_GAMMA_RESPONSE-0.394
- INFLAMMATORY_RESPONSE-0.304
- ESTROGEN_RESPONSE_EARLY-0.289
- HEDGEHOG_SIGNALING-0.269
- APICAL_SURFACE-0.260
- IL6_JAK_STAT3_SIGNALING-0.258
- KRAS_SIGNALING_DN-0.249
- ESTROGEN_RESPONSE_LATE-0.222
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1011 | — | — | 0.854 |
| 2 | MNG1063 | — | — | 0.849 |
| 3 | 5712498e-366d-4b30-b131-ae7209d59842 | — | — | 0.843 |
| 4 | SRR6013505 | — | cohortA4 | 0.843 |
| 5 | MNG646 | — | — | 0.842 |
| 6 | MDT-AP-0359 | Med | Medulloblastoma | 0.841 |
| 7 | TCGA-22-5483-01A-01R-1820-07 | — | cohortMD1 | 0.838 |
| 8 | X7c81e3d9.c538.468a.8a2a.f34513bac230 | — | cohortA3 | 0.836 |
| 9 | 176e93be-1ae5-43f2-a0b5-17f31695e679 | — | — | 0.834 |
| 10 | GSM5359432 | — | — | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.556 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.497 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.494 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.433 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.406 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.333 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.296 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.264 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.226 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.215 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.196 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.147 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.141 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.129 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.095 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.089 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.088 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.057 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.039 | Inavolisib | — uncovered |